Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396326 | 0.90 | KDM4E (0.48) | POLBKMT2AEGFRL3MBTL1KDM4E | |
| SCHEMBL4377954 | 0.90 | SMN1; SMN2 (0.44) | POLBKMT2AEGFRL3MBTL1KDM4E | |
| SCHEMBL4380690 | 0.88 | EGFR (0.40) | CD274POLBKMT2AEGFRL3MBTL1 | |
| SCHEMBL4389093 | 0.88 | KDM4E (0.42) | POLBKMT2AEGFRL3MBTL1KDM4E | |
| SCHEMBL4385121 | 0.86 | EGFR (0.49) | POLBKMT2AEGFRL3MBTL1GLA | |
| SCHEMBL4379975 | 0.85 | EGFR (0.41) | CD274KMT2AEGFRCAPN1 | |
| SCHEMBL4387376 | 0.85 | EGFR (0.43) | CD274KMT2AEGFRMTNR1AMTNR1B | |
| SCHEMBL4394925 | 0.85 | HPGD (0.40) | EGFRCAPN1 | |
| SCHEMBL4389125 | 0.84 | EGFR (0.42) | KMT2AEGFRKDM4ECAPN1 | |
| SCHEMBL4385950 | 0.84 | EGFR (0.43) | POLBKMT2AEGFRKDM4ECAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | CD274 2969/4885PDCD1 2034/4885POLB 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.